{"entity":{"id":"enriqueta-felip","kind":"person","name":"Enriqueta Felip","aka":[],"tldr":"Thoracic oncologist who led IMpower010, establishing adjuvant atezolizumab in lung cancer.","summary":"Enriqueta Felip is Head of the Thoracic Cancers Unit at Vall d'Hebron University Hospital in Barcelona and Professor at the Autonomous University of Barcelona. Her specialisms are lung cancer, targeted therapy and perioperative immunotherapy. She was principal investigator of IMpower010, reported in The Lancet, which tested adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer and established adjuvant immunotherapy in this setting. She is also a leader in trials of EGFR-, ALK- and KRAS-targeted therapy, including osimertinib. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Felip%20E%5BAuthor%5D%20lung%20atezolizumab"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr","alk"],"drugs":["atezolizumab","osimertinib"],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Thoracic Cancers Unit, Vall d'Hebron; Professor, Autonomous University of Barcelona","institutionId":"vall-dhebron","specialisms":["Lung cancer","Targeted therapy","Perioperative immunotherapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Felip%20E%5BAuthor%5D%20lung%20atezolizumab"}],"papers":[{"title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010)","journal":"Lancet","year":2021,"doi":"10.1016/S0140-6736(21)02098-5"},{"title":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2202170","doi":"10.1056/NEJMoa2202170"},{"title":"CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2027187","doi":"10.1056/NEJMoa2027187"},{"title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","journal":"New England Journal of Medicine","year":2023,"url":"https://doi.org/10.1056/NEJMoa2307980","doi":"10.1056/NEJMoa2307980"},{"title":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1801005","doi":"10.1056/NEJMoa1801005"},{"title":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2403614","doi":"10.1056/NEJMoa2403614"}],"orcid":"0000-0002-7620-0098"},"route":"/people/enriqueta-felip/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"},{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"institution":[{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/"}],"paper":[{"id":"paper-checkmate-816-nejm-2022","kind":"paper","name":"CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery","route":"/key-papers/paper-checkmate-816-nejm-2022/"},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/"},{"id":"paper-shaw-crown-lorlatinib-crizotinib-nejm-2020","kind":"paper","name":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","route":"/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/"},{"id":"paper-keynote-189-nejm-2018","kind":"paper","name":"KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation","route":"/key-papers/paper-keynote-189-nejm-2018/"},{"id":"paper-mariposa-nejm-2024","kind":"paper","name":"MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer","route":"/key-papers/paper-mariposa-nejm-2024/"}]}}